{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T14:45:59Z","timestamp":1773240359941,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["12171396"],"award-info":[{"award-number":["12171396"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["12471473"],"award-info":[{"award-number":["12471473"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32171152"],"award-info":[{"award-number":["32171152"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Modelling"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.idm.2025.05.004","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T19:26:18Z","timestamp":1746818778000},"page":"979-988","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dynamic predicting hepatitis B surface antigen decline rate during treatment for patients with chronic hepatitis B"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3995-143X","authenticated-orcid":false,"given":"Ying","family":"Xin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianghong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6787-5018","authenticated-orcid":false,"given":"Kaifa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.idm.2025.05.004_bib1","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1002\/hep4.1767","article-title":"Analysis of HBsAg immunocomplexes and cccDNA activity during and persisting after NAP-based therapy","volume":"5","author":"Bazinet","year":"2021","journal-title":"Hepatology Communications"},{"issue":"4","key":"10.1016\/j.idm.2025.05.004_bib2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3851\/IMP3366","article-title":"Dynamics of HBV surface antigen related end points in chronic hepatitis B infection: A systematic review and meta-analysis","volume":"25","author":"Chen","year":"2020","journal-title":"Antiviral Therapy"},{"issue":"2","key":"10.1016\/j.idm.2025.05.004_bib3","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.idm.2025.05.004_bib4","doi-asserted-by":"crossref","unstructured":"Fan, R., et al. High accuracy model for HBsAg loss based on longitudinal trajectories of serum qHBsAg throughout long-term antiviral therapy. Gut, 73(10), 1725-1736. https:\/\/doi.org\/10.1136\/gutjnl-2024-332182.","DOI":"10.1136\/gutjnl-2024-332182"},{"issue":"9","key":"10.1016\/j.idm.2025.05.004_bib5","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","article-title":"Global, regional, and national burden of hepatitis B, 1990-2019: A systematic analysis for the global burden of disease study 2019","volume":"7","year":"2022","journal-title":"The Lancet Gastroenterology & Hepatology"},{"issue":"1","key":"10.1016\/j.idm.2025.05.004_bib6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jhep.2023.09.039","article-title":"Higher TP53BP2 expression is associated with HBsAg loss in peginterferon-\u03b1-treated patients with chronic hepatitis B","volume":"80","author":"Guan","year":"2024","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1016\/j.idm.2025.05.004_bib7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hep.31240","article-title":"Rapid turnover of hepatitis B virus covalently closed circular DNA indicated by monitoring emergence and reversion of signature-mutation in treated chronic hepatitis B patients","volume":"73","author":"Huang","year":"2021","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.idm.2025.05.004_bib8","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/HEP.0000000000000575","article-title":"Hepatocellular carcinoma reduced, HBsAg loss increased, and survival improved after finite therapy in hepatitis B patients with cirrhosis","volume":"79","author":"Jeng","year":"2024","journal-title":"Hepatology"},{"issue":"10381","key":"10.1016\/j.idm.2025.05.004_bib9","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","article-title":"Hepatitis B","volume":"401","author":"Jeng","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.idm.2025.05.004_bib10","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1007\/s12072-024-10648-8","article-title":"Predictors of HBsAg seroclearance in patients with chronic HBV infection treated with pegylated interferon-\u03b1: A systematic review and meta-analysis","volume":"18","author":"Jiang","year":"2024","journal-title":"Hepatology International"},{"issue":"2","key":"10.1016\/j.idm.2025.05.004_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11020387","article-title":"Use of a deep learning approach for the sensitive prediction of hepatitis B surface antigen levels in inactive carrier patients","volume":"11","author":"Kamimura","year":"2022","journal-title":"Journal of Clinical Medicine"},{"issue":"8","key":"10.1016\/j.idm.2025.05.004_bib12","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: Clinical outcomes and durability","volume":"63","author":"Kim","year":"2014","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.idm.2025.05.004_bib13","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jhep.2024.03.022","article-title":"ALT to qHBsAg ratio predicts long-term HBsAg seroclearance after entecavir cessation in Chinese patients with chronic hepatitis B","volume":"81","author":"Leung","year":"2024","journal-title":"Journal of Hepatology"},{"issue":"11","key":"10.1016\/j.idm.2025.05.004_bib14","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.3760\/cma.j.issn.0366-6999.20132826","article-title":"Kinetics of serum HBsAg in Chinese patients with chronic HBV infection with long-term adefovir dipivoxil treatment","volume":"127","author":"Li","year":"2014","journal-title":"Chinese Medical Journal"},{"issue":"10","key":"10.1016\/j.idm.2025.05.004_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2023.100833","article-title":"Blueprint to hepatitis B elimination in China: A modeling analysis of clinical strategies","volume":"5","author":"Li","year":"2023","journal-title":"JHEP Reports"},{"issue":"6","key":"10.1016\/j.idm.2025.05.004_bib16","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1053\/jhep.2001.29401","article-title":"Chronic hepatitis B","volume":"34","author":"Lok","year":"2001","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.idm.2025.05.004_bib17","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/jvh.13988","article-title":"Association of hepatitis B surface antigen levels with long-term complications in chronic hepatitis B virus infection: A systematic literature review","volume":"31","author":"Mahajan","year":"2024","journal-title":"Journal of Viral Hepatitis"},{"issue":"1","key":"10.1016\/j.idm.2025.05.004_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-pacific clinical practice guidelines on the management of hepatitis B: A 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatology International"},{"issue":"1","key":"10.1016\/j.idm.2025.05.004_bib19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s12072-012-9373-4","article-title":"Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B","volume":"7","author":"Seto","year":"2013","journal-title":"Hepatology International"},{"issue":"1","key":"10.1016\/j.idm.2025.05.004_bib20","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-023-08443-1","article-title":"Establishment of a multi-parameter prediction model for the functional cure of HBeAg-negative chronic hepatitis B patients treated with pegylated interferon\u03b1 and decision process based on response-guided therapy strategy","volume":"23","author":"Tang","year":"2023","journal-title":"BMC Infectious Diseases"},{"issue":"4","key":"10.1016\/j.idm.2025.05.004_bib21","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.idm.2025.05.004_bib22","first-page":"1425","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)","volume":"11","author":"You","year":"2023","journal-title":"Journal of Clinical and Translational Hepatology"},{"issue":"4","key":"10.1016\/j.idm.2025.05.004_bib23","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1053\/j.gastro.2008.07.008","article-title":"HBsAg seroclearance in chronic hepatitis B in Asian patients: Replicative level and risk of hepatocellular carcinoma","volume":"135","author":"Yuen","year":"2008","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.idm.2025.05.004_bib24","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1007\/s12072-024-10666-6","article-title":"Predictive models for functional cure in patients with CHB receiving PEG-IFN therapy based on HBsAg quantification through meta-analysis","volume":"18","author":"Zhang","year":"2024","journal-title":"Hepatology International"}],"container-title":["Infectious Disease Modelling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468042725000363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468042725000363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T13:15:41Z","timestamp":1752585341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468042725000363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2468042725000363"],"URL":"https:\/\/doi.org\/10.1016\/j.idm.2025.05.004","relation":{},"ISSN":["2468-0427"],"issn-type":[{"value":"2468-0427","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dynamic predicting hepatitis B surface antigen decline rate during treatment for patients with chronic hepatitis B","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Modelling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idm.2025.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd\u00e9","name":"copyright","label":"Copyright"}]}}